Compound dossier · evidence, sources, and live market
Tirzepatide
GLP-1 / GIP dual agonist Strong evidence 3 cited studies 34 live vendors
Tirzepatide is a synthetic dual agonist of the GLP-1 and GIP receptors under investigation for metabolic and endocrine research. Laboratories study its effects on glucose regulation and energy balance in preclinical models.
Evidence brief
Tirzepatide is a dual GIP and GLP-1 receptor agonist that has been studied in several phase 3 randomized controlled trials for type 2 diabetes and for weight management.
first-party prices captured 37m ago
Compare by exact vialThe small sealed glass container a compound ships in. size: 5mg (8 vendors)10mg (25 vendors)15mg (7 vendors)20mg (12 vendors)30mg (24 vendors)40mg (4 vendors)50mg (3 vendors)60mg (20 vendors)
Approved by the FDA (Mounjaro, Zepbound), EMA, and MHRA for type-2 diabetes and obesity.Research use only — not medical advice.
These figures are what pepmg still publishes about price: the floor, the middle, the spread and how many sources we track, computed from listings we captured first-party and refreshed on the same schedule as always. We no longer publish the individual listings or the sellers behind them.
Computed from 105 in-stock listings across 34 sources we captured first-party, with bulk vials, blends and statistical outliers excluded so the figures compare like with like. The spread is the highest tracked price divided by the lowest — how much the same milligram varies depending on where you look. The chart is the daily minimum; days we did not capture are left out rather than filled in.
- What the research says about tirzepatide Strong evidence
Tirzepatide is a dual GIP and GLP-1 receptor agonist that has been studied in several phase 3 randomized controlled trials for type 2 diabetes and for weight management.
Read the full review → - Are research peptides safe? What the evidence does and doesn't show Limited evidence
"Are peptides safe?" has no single answer. The compounds sold as research peptides sit at very different points on the evidence scale, from large randomized human trials for a few to animal-only data for many.
Read the full review →
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial PubMed ↗
Despite advancements in care, many people with type 2 diabetes do not meet treatment goals; thus, development of new therapies is needed. We aimed to assess efficacy, safety, and tolerability of novel dual glucose-dependent insulinotropic…
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed ↗
Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor…
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity PubMed ↗
Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. In this phase 3b,…
A few representative studies, each summarized on this site with the PubMed record linked beside it — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. Everything here is research use only.
▸ Why compare $/mg for Tirzepatide?
Per-mg prices for tirzepatide vary due to differences in synthesis scale, purity levels, and vendor sourcing. Comparing prices helps researchers identify cost-effective options without assuming equivalence in quality.
▸ Reading the COA
A third-party COA should confirm peptide identity via mass spectrometry and purity ≥98% by HPLC. Check for common adulterants like truncated sequences or residual solvents, and verify that the reported mg/vial matches the fill weight.
▸ FAQ
▸ Same cluster
| Retatrutide | $2.02/mg | vs Tirzepatide → |
| Semaglutide | $1.22/mg | vs Tirzepatide → |
| Cagrilintide | $4.60/mg | vs Tirzepatide → |
| AOD-9604 | $4.00/mg | vs Tirzepatide → |
| HGH Frag 176-191 | $5.73/mg | vs Tirzepatide → |
| 5-Amino-1MQ | $0.80/mg | vs Tirzepatide → |
| Survodutide | $7.39/mg | vs Tirzepatide → |
| Mazdutide | $5.72/mg | vs Tirzepatide → |
| Teduglutide | $2.37/mg | |
| Orforglipron | $21.50/mg | vs Tirzepatide → |
| Tesofensine | $159.98/mg | vs Tirzepatide → |
| SLU-PP-332 | $3.33/mg | vs Tirzepatide → |
| BAM15 | $1.96/mg | vs Tirzepatide → |
| AICAR | $0.63/mg | vs Tirzepatide → |
| Adipotide | $7.60/mg | vs Tirzepatide → |
| L-Carnitine | $9.90/mg |